| [1] |
McMillan T, Wilson L, Ponsford J, et al. The Glasgow outcome scale-40 years of application and refinement[J]. Nat Rev Neurol, 2016, 12(8): 477-485.
|
| [2] |
Carney N, Totten AM, O’reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition[J]. Neurosurgery, 2017, 80(1): 6-15.
|
| [3] |
Hammad A, Westacott L, Zaben M. The role of the complement system in traumatic brain injury: a review[J]. J Neuroinflamm, 2018, 15(1): 24.
|
| [4] |
Cekanaviciute E, Buckwalter MS. Astrocytes: integrative regulators of neuroinflammation in stroke and other neurological diseases[J]. Neurotherapeutics, 2016, 13(2): 685-701.
|
| [5] |
Simon DW, McGeachy MJ, Bayır H, et al. The far-reaching scope of neuroinflammation after traumatic brain injury[J]. Nat Rev Neurol, 2017, 13(3): 171-191.
|
| [6] |
Fluiter K, Opperhuizen AL, Morgan BP, et al. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice[J]. J Immunol, 2014, 192(3): 2339-2348.
|
| [7] |
Ruseva MM, Ramaglia V, Morgan BP, et al. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice[J]. Proc Natl Acad Sci USA, 2015, 112(46): 14319-14324.
|
| [8] |
Rich MC, Keene CN, Neher MD, et al. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains[J]. Neurosci Lett, 2016, 617: 188-194.
|
| [9] |
Alawieh A, Langley EF, Weber S, et al. Identifying the role of complement in triggering neuroinflammation after traumatic brain injury[J]. J Neurosci, 2018, 38(10): 2519-2532.
|
| [10] |
Gao M, Dong Q, Yao H, et al. Systemic administration of induced neural stem cells regulates complement activation in mouse closed head injury models[J]. Sci Rep, 2017, 7(1): 45989.
|
| [11] |
Gao M, Dong Q, Lu Y, et al. Induced neural stem cell-derived astrocytes modulate complement activation and mediate neuroprotection following closed head injury[J]. Cell Death Dis, 2018, 24, 9(2): 101.
|
| [12] |
Yao H, Gao M, Ma J, et al. Transdifferentiation-induced neural stem cells promote recovery of middle cerebral artery stroke rats[J]. PLoS One, 2015, 10(9): e0137211.
|
| [13] |
Mertens J, Marchetto MC, Bardy C, et al. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience[J]. Nat Rev Neurosci, 2016, 17(7): 424-437.
|
| [14] |
Mollinari C, Zhao J, Lupacchini L, et al. Transdifferentiation: a new promise for neurodegenerative diseases[J]. Cell Death Dis, 2018, 9(8): 830.
|
| [15] |
Sacks SH, Zhou W. The role of complement in the early immune response to transplantation[J]. Nat Rev Immunol, 2012, 12(6): 431-442.
|
| [16] |
Wagner E, Frank MM. Therapeutic potential of complement modulation[J]. Nat Rev Drug Discov, 2010, 9(1): 43-56.
|
| [17] |
Griesemer A, Yamada K, Sykes M. Xenotransplantation: immunological hurdles and progress toward tolerance[J]. Immunol Rev, 2014, 258(1): 241-258.
|
| [18] |
Rancan M, Morganti-Kossmann MC, Barnum SR, et al. Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice[J]. J Cereb Blood Flow Metab, 2003, 23(9): 1070-1074.
|
| [19] |
Leinhase I, Schmidt OI, Thurman JM, et al. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury[J]. Exp Neurol, 2006, 199(2): 454-464.
|